About Our Acute Pain Pledge
Kowa Pharmaceuticals America, Inc., is continually dedicated to putting patients, healthcare providers, and our people at the center of everything we do. That is why we are committed to listening and moving forward while entering the acute pain space.
As a step in the right direction, we are committed to making a difference through listening, responsible action, and transparency. First by listening to the needs of doctors, patients, first responders, families, and communities.
We are committed to open conversations and to making a positive impact in partnership with the larger community—so that a new future is possible. And as we continue to hear from members of the community, we will add resources, guidance, and tools.
Our corporate commitment is guided by the following key pillars:
Responsible and appropriate use of our products
Development of educational resources for healthcare providers and patients to address potential gaps in the treatment of acute pain
Ensuring transparency and integrity in all that we do
The Impact of Acute Pain
The experience of acute pain is highly individual and there is no one-size-fits-all approach to pain management in adults.
What Is Acute Pain?
Acute pain can be characterized as a sudden sharp pain lasting less than 4 weeks, and chronic pain is characterized by pain that lasts more than 3 months.1,2
Acute pain accounts for 42% of patients who experienced pain-related events in the US.3
According to our survey, over 70% of patients want information from their doctors on side effects, risks of dependence, and safe dosing. 97% of respondents reported that a doctor’s discussion guide is a valuable resource.4
Kowa Pharmaceuticals America, Inc.,Is Committed to Helping Physicians Treat Certain Types of Acute Pain
Acute Pain Fact Sheet
A guide to use with patients during discussions about opioids and acute pain management.
Patient Opiate Conversation Guide
Get help addressing the risks and concerns of abuse, addiction, misuse, and dependence.
A Commitment to Responsible Use
“We are committed to learning how we can positively impact healthcare providers and patients through support, education, and initiatives. We will continue to put our values and people at the core of all we do.”
Ben Stakely, Chief Executive Officer and President
Opioid analgesics can be an important option for healthcare providers to appropriately manage acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Notwithstanding the medical need, Kowa recognizes that the use of prescription opioid medications is associated with the risks of abuse, addiction, and diversion.
Kowa Pharmaceutical America, Inc.’s commitment starts with listening to and understanding the needs of the patient, healthcare providers, and the overall pain community. As part of our commitment to being a responsible partner, we will be continuously listening to and securing feedback from the community to understand how we can best provide support and foster responsible and appropriate use.
Get in Touch
As part of our commitment to open conversations and to making a positive impact in partnership with the larger community—we want to hear from you.
Send us an email
using the button below.
Manion J, Waller MA, Clark T, Massingham JN, Neely GG. Developing modern pain therapies. Frontiers in Neuroscience. 2019;13:1370.
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain. Center for Disease Control and Prevention MMWR Recommendations and Reports. 2016;65(1).
Aggregated claims data deliverable from Symphony’s APLD offering.
Kowa Pharmaceuticals America, Inc. US Patient Acute Pain Management Perceptions and Behaviors Survey. Accessed March 21, 2022. Intended for US patients only. Methodology Statement: The Kowa Pharmaceuticals America, Inc. US Patient Acute Pain Management Perceptions and Behaviors Survey was conducted online within the United States by Real Chemistry on behalf of Kowa Pharmaceuticals America, Inc., from December 20, 2021–January 16, 2022 among 350 US adults ages 18-81. Survey participants included those who have been treated by a doctor for acute pain over the last 18 months and were offered a medication to manage the pain.